IL320572A - Anti-ctla antibody compositions and related methods - Google Patents
Anti-ctla antibody compositions and related methodsInfo
- Publication number
- IL320572A IL320572A IL320572A IL32057225A IL320572A IL 320572 A IL320572 A IL 320572A IL 320572 A IL320572 A IL 320572A IL 32057225 A IL32057225 A IL 32057225A IL 320572 A IL320572 A IL 320572A
- Authority
- IL
- Israel
- Prior art keywords
- related methods
- antibody compositions
- ctla antibody
- ctla
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263382398P | 2022-11-04 | 2022-11-04 | |
| PCT/EP2023/080627 WO2024094831A1 (en) | 2022-11-04 | 2023-11-03 | Anti-ctla antibody compositions and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL320572A true IL320572A (en) | 2025-07-01 |
Family
ID=88731370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL320572A IL320572A (en) | 2022-11-04 | 2025-04-29 | Anti-ctla antibody compositions and related methods |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250340643A1 (en) |
| EP (1) | EP4611898A1 (en) |
| JP (1) | JP2025536574A (en) |
| KR (1) | KR20250099736A (en) |
| CN (1) | CN120202024A (en) |
| AR (1) | AR130954A1 (en) |
| AU (1) | AU2023374714A1 (en) |
| IL (1) | IL320572A (en) |
| WO (1) | WO2024094831A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| EP1865986B1 (en) * | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Anti-ctla-4 antibody compositions |
| JP2019514889A (en) * | 2016-04-25 | 2019-06-06 | メディミューン,エルエルシー | Composition comprising a co-formulation of anti-PD-L1 and anti-CTLA-4 antibody |
-
2023
- 2023-11-03 JP JP2025524800A patent/JP2025536574A/en active Pending
- 2023-11-03 US US19/126,456 patent/US20250340643A1/en active Pending
- 2023-11-03 CN CN202380077036.7A patent/CN120202024A/en active Pending
- 2023-11-03 EP EP23801711.5A patent/EP4611898A1/en active Pending
- 2023-11-03 KR KR1020257018375A patent/KR20250099736A/en active Pending
- 2023-11-03 AR ARP230102949A patent/AR130954A1/en unknown
- 2023-11-03 WO PCT/EP2023/080627 patent/WO2024094831A1/en not_active Ceased
- 2023-11-03 AU AU2023374714A patent/AU2023374714A1/en active Pending
-
2025
- 2025-04-29 IL IL320572A patent/IL320572A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR130954A1 (en) | 2025-02-05 |
| KR20250099736A (en) | 2025-07-02 |
| US20250340643A1 (en) | 2025-11-06 |
| EP4611898A1 (en) | 2025-09-10 |
| CN120202024A (en) | 2025-06-24 |
| JP2025536574A (en) | 2025-11-07 |
| WO2024094831A1 (en) | 2024-05-10 |
| AU2023374714A1 (en) | 2025-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL317782A (en) | Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates | |
| IL319931A (en) | Anti-cd122 antibodies and uses thereof | |
| MX2018012651A (en) | Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies. | |
| IL308695A (en) | Anti-nkg2a antibodies and compositions | |
| IL318296A (en) | Anti-trop2 antibody and conjugate thereof | |
| EP4201958A4 (en) | Anti-ctla-4 antibody and use thereof | |
| IL327202A (en) | Anti-cdh17 antibodies and uses thereof | |
| IL320586A (en) | Anti-trem2 antibody and uses thereof | |
| HRP20260098T1 (en) | Anti-gprc5d monoclonal antibodies and uses thereof | |
| IL317391A (en) | Novel anti-lilrb4 antibodies and uses thereof | |
| IL304807A (en) | Anti-pd-1 antibody and use thereof | |
| CA3250452A1 (en) | Anti-5t4 antibodies and uses thereof | |
| AU2021378575A9 (en) | Anti-tspan8-anti-cd3 bispecific antibody and anti-tspan8 antibody | |
| IL316510A (en) | Anti-b7h3 antibody and uses thereof | |
| IL317849A (en) | Anti-slc34a2 monoclonal antibodies and uses thereof | |
| IL319145A (en) | Novel anti-lilrb2 antibodies and uses thereof | |
| IL325396A (en) | Anti-gpc3 antibody or antigen-binding fragment and use thereof | |
| IL310329A (en) | Compositions and methods for anti-pacap antibodies | |
| IL320972A (en) | Anti-tfr1 antibodies and uses thereof | |
| EP4223776A4 (en) | Anti-pd-l1 antibody and use thereof | |
| EP4237443A4 (en) | Anti-sars-cov-2 antigen antibodies and related compositions and methods | |
| CA3272252A1 (en) | Anti-ctla antibody compositions and related methods | |
| GB202303531D0 (en) | Antibodies and uses thereof | |
| IL326262A (en) | Anti-GPRC5D antibodies and composition | |
| CA3300108A1 (en) | Anti-gprc5d antibodies and compositions |